Preview

Медицинский альманах

Расширенный поиск

Сахарный диабет 2-го типа и неалкогольная жировая болезнь печени - болезни современности

https://doi.org/10.21145/2499-9954-2017-6-130-135

Полный текст:

Аннотация

Сахарный диабет 2 типа (СД 2 типа) часто сочетается с неалкогольной жировой болезнью печени (НАЖБП). Для лечения СД в настоящее время существует широкий спектр сахароснижающих препаратов, но заболевания печени накладывают ограничения на выбор сахароснижающей терапии. Новые классы лекарственных средств, действие которых основано на эффектах инкретинов, ингибиторов НГЛТ-2 открывают новые перспективы терапии СД 2 в сочетании с НАЖБП.

Об авторах

Е. В. Бирюкова
ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова»
Россия


С. В. Родионова
ГБУЗ «Московский клинический научно-практический центр Департамента здравоохранения г. Москвы имени А.С. Логинова»
Россия


Список литературы

1. Sung K.C., Kim S.H. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011. № 96 (4). Р. 1093-1097.

2. Leite N.C., Salles G.F., Araujo A. et al. Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009. № 29. Р. 113-119.

3. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008. № 28 (4). Р. 339-350.

4. Browning J.D., Szczepaniak L.S., Dobbins R. et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004. № 40. Р. 1387-1395.

5. Lazo M., Hernaez R., Eberhardt M.S. et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey. 1988-1994. Am J Epidemiol. 2013. № 178. Р. 38-45.

6. Mc Cullough A.J. The epidemiology and risk factors of NASH. Hepatology. 2013. № 58 (5). Р. 1644-1654.

7. Bae J.C., Cho Y.K., Lee W.Y. et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol. 2010. № 105. Р. 2389-2395.

8. Yamazaki H., Tsuboya T., Tsuji K. et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus. Diabetes Care 2015. http://dx.doi. org/10.2337/dc15-0140.

9. McPherson S., Hardy T., Henderson E. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis & clinical management. J Hepatol. 2014. http://dx.doi.org/10.1016/j. jhep.2014.11.034.

10. Targher G., Bertolini L., Rodella S. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008. № 51. Р. 444-450. http://dx.doi. org/10.1007/s00125-007-0897-4.

11. Choudhury J., Sanyal A.J. Clinical aspects of fatty liver disease. Semin Liver Dis. 2004. № 24. Р. 349-362.

12. Ryysy L., Häkkinen A.M., Goto T. et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000. № 49. Р. 749-758.

13. Fracanzani A.L., Valenti L., Bugianesi E. et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008. № 48. Р. 792-798.

14. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011. № 43. Р. 617-649.

15. Wong V.W., Wong G.L., Choi P.C. et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010. № 59. Р. 969-974.

16. AGA. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012. № 142. Р. 1592-1609.

17. Звенигородская Л.А., Хомерики С.Г., Егорова Е.Г. Морфологические изменения печени при инсулинорезистентности. РМЖ. 2008. № 4. С. 161-164.

18. Torres D.M., Harrison S.A. Nonalcoholic Fatty Liver Disease / Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / ed. by M. Feldman, L.S. Friedman, L.J. Brandt. 2015.

19. Courcoulas A.P., Belle S.H., Neiberg R.H. et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg. 2015. ttp://dx.doi.org/10.1001/jamasurg.2015.1534.

20. Xiang Z., Chen Y.P., Ma K.F. et al. The role of ursodeoxycholic acid in nonalcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013ю. № 13. 140 р.

21. Schurks M., Glynn R.J., Rist P.M. Effects of vitamin E et al. on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010. № 341. 5702 р.

22. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015. № 385 (9972). Р. 956-965.

23. Tolman K.G., Fonseca V., Dalpiaz A., Tan M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007. № 30. Р. 734-743.

24. Loomba R., Lutchman G., Kleiner D.E. et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2009. № 29 (2). Р. 172-182.

25. Krakoff J., Clark J.M., Crandall J.P. et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity. 2010. № 18 (9). Р. 1762-1767.

26. Li Y., Liu L., Wang B. et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013. № 1 (1). Р. 57-64.

27. Zhang Z.J., Zheng Z.J., Shi R. et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012. № 97 (7). Р. 2347-2353.

28. Belfort R., Harrison S.A., Brown K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006. № 355. Р. 2297-307.

29. Aithal G.P., Thomas J.A., Kaye P.V. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008. № 135. Р. 1176-1184.

30. Goh G., Pagadala M. Diabetes mellitus, insulin, sulfonylurea and advanced fibrosis in non-alcoholic fatty liver disease. J Diabetes Metab. 2014. № 5. Р. 1-5.

31. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancerrelatedmortality for patients with type 2 diabeteswho use sulfonylureas or insulin. Diabetes Care. 2006. № 29. Р. 254-258.

32. Hazlehurst J.M., Woods C., Marjot T. Non-alcoholic fatty liver disease et al. and diabetes. Metabolism. 2016. № 65 (8). Р. 1096-1108.

33. Arase Y., Kawamura Y., Seko Y. et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res. 2013. № 43. Р. 1163-1168. http://dx.doi.org/10.1111/hepr.12077.

34. Iwasaki T., Yoneda M., Inamori M. et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 2011. № 58. Р. 2103-2105. http://dx.doi. org/10.5754/hge11263.

35. Macauley M., Hollingsworth K.G., Smith F.E. et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015. № 100. Р. 1578-1585.

36. Svegliati-Baroni G., Saccomanno S., Rychlicki C. et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011. № 31. Р. 1285-1297.

37. Klonoff D.C., Buse J.B., Nielsen L.L. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients withtype 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008. № 24. Р. 275-286.

38. Armstrong M., Gaunt P., Aithal G., Parker R. Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebocontrolled phase. Abstr G01, EASL. 2015.

39. Hayashizaki-Someya Y., Kurosaki E., Takasu T. et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015. № 754. Р. 19-24.


Для цитирования:


Бирюкова Е.В., Родионова С.В. Сахарный диабет 2-го типа и неалкогольная жировая болезнь печени - болезни современности. Медицинский альманах. 2017;(6):130-135. https://doi.org/10.21145/2499-9954-2017-6-130-135

For citation:


Biryukova E.V., Rodionova S.V. Diabetes mellitus of the 2nd type and non-alcoholic fatty liver disease - diseases of modern times. Medical Almanac. 2017;(6):130-135. (In Russ.) https://doi.org/10.21145/2499-9954-2017-6-130-135



Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1997-7689 (Print)
ISSN 2499-9954 (Online)